MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction (MASTER-II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01869738
Recruitment Status : Terminated (low enrollment rate)
First Posted : June 5, 2013
Last Update Posted : September 2, 2015
Information provided by (Responsible Party):

May 28, 2013
June 5, 2013
September 2, 2015
June 2013
August 2015   (Final data collection date for primary outcome measure)
  • rate of complete ST-segment resolution within 60-90 minutes [ Time Frame: 60-90 minutes post-procedure ]
  • The primary safety endpoint is a composite of all-cause death or recurrent target vessel myocardial infarction (TV re-MI) at 365 days post-procedure, powered to demonstrate non-inferiority of the MGuard™ Prime Stent compared to the control arm. [ Time Frame: 365 days post-procedure ]
Same as current
Complete list of historical versions of study NCT01869738 on Archive Site
  • Infarct size assessed by cardiac magnetic resonance imaging (MRI) [ Time Frame: 5 days post-procedure ]
  • In-stent late lumen loss (LLL) [ Time Frame: 13 months post-procedure ]
Same as current
Not Provided
Not Provided
MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction
MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction
To evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of blocked arteries in coronary arteries in patients undergoing a stenting procedure due to having a heart attack. The MGuard Prime stent wil be compared to other FDA approved bare-metal (BMS) or drug-eluting (DES) coronary stents. The hypotheses are that (1) the MGuard Prime stent will achieve a higher rate of complete ST-segment resolution as seen on the post-procedure ECG as compared to the comparator stent, and will have a similar effect on the rate of all-cause death or recurrent target vessel myocardial infarction at 365 days post-procedure.
Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
ST Elevation Myocardial Infarction
  • Device: MGuard Prime
  • Device: (BMS/DES)
  • Experimental: MGuard Prime
    MGuard Prime stent
    Intervention: Device: MGuard Prime
  • Active Comparator: Control
    (BMS/DES) Includes FDA approved bare metal or drug eluting stents, including ENDEAVOR, TAXUS Liberte, XIENCE Prime, PROMUS Element, ION, RESOLUTE, Driver, Vision, VeriFlex and Integrity.
    Intervention: Device: (BMS/DES)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2015
August 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is more than 18 years of age
  • Subject is experiencing clinical symptoms consistent with acute myocardial infarction (AMI) of more than 30 minutes and less than 12 hours in duration.
  • ST elevation more than 2 mm per lead in more than 2 contiguous leads is present in one ECG prior to consent.
  • Subject agrees to all required follow-up procedures and visits.
  • Subject or legal representative provides written, informed consent.
  • The target lesion is a de novo lesion in a native coronary artery.
  • Based on coronary anatomy, PCI is indicated for the culprit lesion with anticipated use of stenting.
  • The reference vessel diameter (RVD) of the infarct lesion is 2.75 to 4.0 mm by visual assessment, assessed either at baseline (if direct stenting is planned), or after pre-dilatation or thrombus aspiration (if direct stenting is not planned).
  • The entire lesion length requiring treatment is less than 24 mm (able to be covered by a single study stent), assessed either at baseline (if direct stenting is planned), or after pre-dilatation or thrombus aspiration (if direct stenting is not planned)
  • TIMI flow of 2/3 is present prior to randomization (in case of baseline TIMI flow 0/1, blood flow must be restored).

Exclusion Criteria:

  • Left bundle branch block (LBBB), paced rhythm, or other ECG abnormality interfering with assessment of ST-segment.
  • Currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints.
  • A previous coronary interventional procedure of any kind within 30 days prior to the procedure.
  • Female patients of childbearing potential.
  • Subject undergoing cardiopulmonary resuscitation (patients in whom cardiopulmonary resuscitation was successfully performed and in whom normal mental status was achieved, may be enrolled).
  • Cardiogenic shock (SBP less than 80 mmHg for more than other hemodynamic support device for hypotension).
  • The subject requires a staged procedure of the target vessel (including branches) within 12 months or of any non-target vessel within 7 days post-procedure.
  • The target lesion requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to excimer laser, rotational atherectomy, etc.). Manual thrombus aspiration may be used per operator discretion, but rheolytic thrombectomy is only permitted for procedural complications after randomization.
  • Prior administration of thrombolytic therapy for the current admission
  • Co-morbid condition(s) that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial.
  • Concurrent medical condition with a life expectancy of less than 12 months.
  • History of cerebrovascular accident or transient ischemic attack within the last 6 months, or any permanent neurologic deficit
  • Prior intracranial bleed at any time, or known intracranial pathology (e.g. tumor, arteriovenous malformation, or aneurysm).
  • Active or recent site of major bleeding within 6 months.
  • History of bleeding diathesis or coagulopathy or inability to accept blood transfusions.
  • Known hypersensitivity or contraindication to either i) aspirin, or heparin and bivalirudin; or ii) clopidogrel , ticlopidine, prasugrel and ticagrelor; or iii) cobalt or nickel; or iv) contrast media, which cannot be adequately pre-medicated (prior anaphylaxis, however, is an absolute contraindication to enrollment).
  • Known serum creatinine level more than 2.5 mg/dl, hemoglobin less than 10 g/dL or platelet count less than 150,000 for the present admission or within 7 days prior to index procedure, if available.
  • Surgery planned or any other reason necessitating discontinuation of dual anti-platelet therapy (aspirin and an ADP antagonist) within 12 months
  • Aortic dissection or mechanical complication of STEMI
  • Unprotected left main stenosis more than 50%.
  • Multi-vessel intervention required during the index procedure.
  • Excessive tortuosity, calcification or diffuse distal disease
  • A non-infarct lesion with stenosis more than 50% is present in the target vessel
  • Target lesion is a bifurcation with a side branch more than 2.0 mm in diameter.
  • Target lesion at the site of or within a vessel with a previously implanted stent
  • Target lesion is within a bypass graft conduit, or can only be reached by passing the study stent through a bypass graft conduit
  • In the Investigator's opinion the lesion/vessel is unsuitable for treatment with the study stent for any reason.
  • The lesion requires use of atherectomy, thrombectomy (not including manual thrombus aspiration catheters), laser devices, or proximal or distal embolic protection devices prior to randomization.
  • Aortic dissection or mechanical complication of STEMI
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Belgium,   Czech Republic,   Estonia,   Finland,   France,   Germany,   Israel,   Netherlands,   Poland,   Spain,   United Kingdom,   United States
Not Provided
Not Provided
Not Provided
Not Provided
August 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP